Reaction

Vulvovaginal Pruritus reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 4,983 reports · 61 co-occurring drugs

As of the last recalculation, Vulvovaginal Pruritus appears in 4,983 FAERS reports alongside 61 co-occurring drug terms. The strongest observed disproportionality signal is MICONAZOLE NITRATE (PRR 336.3).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Miconazole Nitrate	616	336.3	361.9
Estradiol	344	17.8	17.9
Conjugated Estrogens	228	17.1	17.1
Estrogens, Conjugated	225	16.5	16.6
Etonogestrel And Ethinyl Estradiol	80	15.3	15.3
Empagliflozin	207	13.4	13.4
Canagliflozin	86	12.2	12.2
Copper	110	10.9	10.9
Estradiol Gel 0.1%	109	10.3	10.3
Estradiol Transdermal	109	10.3	10.3
Dapagliflozin	65	8.7	8.7
Drs. Clotrimazole	23	8.3	8.4
Family Wellness Clotrimazole	23	8.3	8.4
Clotrimazole Topical	23	8.3	8.4
Dicyclomine Hydrochloride	28	8.2	8.3
Clotrimazole	23	7.9	7.9
Levonorgestrel	271	5.9	5.9
Rabeprazole	30	5.7	5.7
Fexofenadine Hcl	12	5.4	5.4
Fluconazole	81	4.9	4.9
Triamcinolone Acetonide Ointment Usp, 0.05%	26	4.7	4.7
Thyroid, Porcine	11	4.3	4.3
Fenofibrate	34	4.0	4.0
Irbesartan	41	3.9	3.9
Progesterone	21	3.8	3.9
Mirabegron	35	3.8	3.8
Vibegron	7	3.7	3.7
Biotin	27	3.6	3.6
Triamcinolone Acetonide	26	3.5	3.5
Glimepiride	32	3.4	3.4
Fexofenadine Hydrochloride	17	3.3	3.3
Calcium	108	3.1	3.1
Cladribine	7	3.0	3.0
Trazodone Hydrochloride	11	2.9	2.9
Rizatriptan Benzoate	7	2.9	2.9
Oxybutynin Chloride	6	2.9	2.9
Clobetasol Propionate Ointment Usp, 0.05%	7	2.8	2.8
Clobetasol Propionate	7	2.8	2.8
Sotalol Hydrochloride	11	2.8	2.8
Vilazodone Hydrochloride	6	2.7	2.7
Fexofenadine	10	2.5	2.5
Peginterferon Alfa-2A	32	2.5	2.5
Oxybutynin	17	2.4	2.4
Sitagliptin And Metformin Hydrochloride	12	2.3	2.3
Fesoterodine Fumarate	6	2.3	2.3
Etonogestrel	26	2.3	2.3
Liraglutide	26	2.2	2.2
Iohexol	4	2.0	2.0
Oral Semaglutide	35	2.0	2.0
Ribavirin	30	2.0	2.0
Bimekizumab	9	1.8	1.8
Crisaborole	4	1.7	1.7
Palbociclib	36	1.6	1.6
Rimegepant Sulfate	4	1.3	1.3
Tenofovir Disoproxil Fumarate	10	1.3	1.3
Drospirenone And Ethinyl Estradiol	13	1.2	1.2
Dulaglutide	26	1.2	1.2
Ixekizumab	10	1.1	1.1
Leuprolide Acetate	20	1.1	1.1
Dalfampridine	18	1.0	1.0
Dupilumab	65	0.6	0.6

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.